2015
DOI: 10.1182/blood-2014-10-609032
|View full text |Cite
|
Sign up to set email alerts
|

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation

Abstract: The success of allogeneic hematopoietic cell transplantation (HCT) is typically assessed as individual complications, including graft-versus-host disease (GVHD), relapse, or death, yet no one factor can completely characterize cure without ongoing morbidity. We examined a novel composite end point of GVHD-free/relapse-free survival (GRFS) in which events include grade 3-4 acute GVHD, systemic therapy-requiring chronic GVHD, relapse, or death in the first post-HCT year. In 907 consecutive University of Minnesot… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

17
339
2
2

Year Published

2015
2015
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 430 publications
(360 citation statements)
references
References 21 publications
17
339
2
2
Order By: Relevance
“…31,36,37 aGVHD was defined and graded from 0 to 4 based on the Seattle criteria. 38 cGVHD was defined and graded according to the NIH criteria.…”
Section: Definitions and Evaluationmentioning
confidence: 99%
“…31,36,37 aGVHD was defined and graded from 0 to 4 based on the Seattle criteria. 38 cGVHD was defined and graded according to the NIH criteria.…”
Section: Definitions and Evaluationmentioning
confidence: 99%
“…14 The pertinence of this GVHD and relapse-free survival (GRFS) to evaluate the overall outcome after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) integrating a quality of life assessment was recently confirmed. 15 Statistics were computed using R-project 3.1.3 software (www.r-project.org).…”
Section: Statistical Analysesmentioning
confidence: 99%
“…We tested also the recent composite end point GRFS (21), introduced in the 2015, which reflects the survival free of 102 major complications. GRFS events were defined as grade 3-4 acute GVHD or chronic GVHD requiring systemic immunosuppressive treatment at any time, disease relapse or death from any cause during the first 12 and 36 months 104 after alloSCT.…”
mentioning
confidence: 99%